Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials.
van der Most RG, Clément F, Willekens J, Dewé W, Walravens K, Vaughn DW, Leroux-Roels G. van der Most RG, et al. Clin Vaccine Immunol. 2017 Jun 5;24(6):e00553-16. doi: 10.1128/CVI.00553-16. Print 2017 Jun. Clin Vaccine Immunol. 2017. PMID: 28446441 Free PMC article. Clinical Trial.
Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
Leroux-Roels I, Roman F, Forgus S, Maes C, De Boever F, Dramé M, Gillard P, van der Most R, Van Mechelen M, Hanon E, Leroux-Roels G. Leroux-Roels I, et al. Vaccine. 2010 Jan 8;28(3):849-57. doi: 10.1016/j.vaccine.2009.10.017. Epub 2009 Oct 14. Vaccine. 2010. PMID: 19835828 Clinical Trial.
Seeking help: B cells adapting to flu variability.
van der Most RG, Roman FP, Innis B, Hanon E, Vaughn DW, Gillard P, Walravens K, Wettendorff M. van der Most RG, et al. Sci Transl Med. 2014 Jul 23;6(246):246ps8. doi: 10.1126/scitranslmed.3008409. Sci Transl Med. 2014. PMID: 25101885
Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting.
Penn-Nicholson A, Geldenhuys H, Burny W, van der Most R, Day CL, Jongert E, Moris P, Hatherill M, Ofori-Anyinam O, Hanekom W; Vaccine Study Team; Bollaerts A, Demoitie MA, Kany Luabeya AK, De Ruymaeker E, Tameris M, Lapierre D, Scriba TJ. Penn-Nicholson A, et al. Vaccine. 2015 Jul 31;33(32):4025-34. doi: 10.1016/j.vaccine.2015.05.088. Epub 2015 Jun 10. Vaccine. 2015. PMID: 26072017 Free PMC article. Clinical Trial.
Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial.
Leroux-Roels G, Marchant A, Levy J, Van Damme P, Schwarz TF, Horsmans Y, Jilg W, Kremsner PG, Haelterman E, Clément F, Gabor JJ, Esen M, Hens A, Carletti I, Fissette L, Tavares Da Silva F, Burny W, Janssens M, Moris P, Didierlaurent AM, Van Der Most R, Garçon N, Van Belle P, Van Mechelen M. Leroux-Roels G, et al. Clin Immunol. 2016 Aug;169:16-27. doi: 10.1016/j.clim.2016.05.007. Epub 2016 May 25. Clin Immunol. 2016. PMID: 27236001 Free article. Clinical Trial.
106 results